Wolfe starts Biogen at Peer Perform, sees limited downside risk
Wolfe Research analyst Alexandria Hammond initiated coverage of Biogen (BIIB) with a Peer Perform rating. With a legacy portfolio that ...
Ticker: Biogen Alzheimer’s drug gets second look in EU; Ford takes $165M hit on slow recall
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
European committee takes a second look at Alzheimer's drug and now says it should be approved
A European regulatory committee now recommends approval of the Alzheimer's treatment lecanemab a few months after rejecting ...
BioPharma Dive17h
Eisai wins over European regulators on Alzheimer’s drug Leqembi
A key regulatory committee sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing Leqembi up for authorization in a major market.
Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug
Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease ...
Le Lézard23h
PEGylated Proteins Market Set to Reach USD 19.1 Billion by 2031, Driven by Advancements in Drug Delivery: - Market Research Intellect
The PEGylated Proteins Market is primarily driven by the growing demand for effective drug delivery systems, particularly in the treatment of chronic diseases such as cancer, hepatitis, and rheumatoid ...
Amazon's push into telehealth knocks shares of Hims & Hers
Shares of Hims & Hers Health slumped 15% on Thursday after Amazon.com launched a rival service that offers upfront pricing ...
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight
DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...
MarketWatch1d
Biogen Inc. stock underperforms Wednesday when compared to competitors
Shares of Biogen Inc. BIIB slid 1.48% to $165.79 Wednesday, on what proved to be an all-around favorable trading session for ...
Business Insider1d
Biogen initiated with a Neutral at Citi
Citi analyst Geoff Meacham initiated coverage of Biogen (BIIB) with a Neutral rating and $190 price target The company’s strategy to offset core franchise erosion has been to develop assets with ...